Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 06 - 16 save search
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Published: 2021-06-16 (Crawled : 23:00) - globenewswire.com
ARGX | $375.08 1.72% 1.7% 1.3K
|
Health Technology
|
| O: -0.75%
H: 2.48%
C: 1.48%
treatment results phase 3 trial trial results lancet
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
TARS | $33.71 4.4% 4.27% 230K
|
Health Technology
|
| O: 0.23%
H: 1.5%
C: 0.71%
disease phase 1 vaccine trial phase 3 phase 2
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
STSA | $1.1 -0.9% -0.91% 0
|
Health Technology
|
| O: -0.41%
H: 1.43%
C: 1.02%
phase 1 positive results trial phase 3 phase 2
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
Published: 2021-06-16 (Crawled : 13:00) - biospace.com/
APRE | $5.37 4.88% 6.3% 2.7K
|
Health Technology
|
| O: 50.72%
H: 6.7%
C: -26.4%
phase 1 trial phase 3 phase 2 aml
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -4.93%
disease phase 1 trial phase 3 phase 2
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
ALT | $7.57 1.34% 1.19% 3.9K
|
Commercial Services
|
| O: 2.19%
H: 34.76%
C: 13.99%
phase 1 positive trial phase 3 phase 2 obesity
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Published: 2021-06-16 (Crawled : 11:00) - globenewswire.com
SWTX | $44.0 2.59% 2.43% 870K
|
Health Technology
|
| O: 0.08%
H: 1.02%
C: -0.11%
phase 1 children trial phase 3 phase 2
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Published: 2021-06-16 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.15%
H: 0.3%
C: -0.78%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.7%
H: 2.12%
C: -1.43%
covid casirivimab phase 3 trial sars-cov-2
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
TOVX | News | $0.3769 -8.3% 7.46% 1.2M
|
Manufacturing
TXN | $165.47 1.25% 6.76% 4.3M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.